Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHED/GLA 2022-1
2022-501187-18-00Phase 3Authorised
- Sponsor
- Saarland University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL), primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), intravascular large B-cell lymphoma (IVLBCL) and 10 more (2 arms), sponsored by Saarland University. Primary endpoint: Progression-free survival. Planned start Apr 2023; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)intravascular large B-cell lymphoma (IVLBCL)Epstein-Barr virus-positive diffuse large B-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2022-501187-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501187-18-00.